Schering-Plough Free cash flow decreased by 70.0% to -$14.22M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 70.0%, from -$8.37M to -$14.22M. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|
| Value | -$6.00M | -$6.00M | -$6.00M | -$6.00M | -$8.37M | -$14.22M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -39.3% | -70.0% |
| YoY Change | — | — | — | — | -39.3% | -70.0% |